CN114630668A - 一种Aprocitentan晶型及其制备方法和用途 - Google Patents
一种Aprocitentan晶型及其制备方法和用途 Download PDFInfo
- Publication number
- CN114630668A CN114630668A CN202080076776.5A CN202080076776A CN114630668A CN 114630668 A CN114630668 A CN 114630668A CN 202080076776 A CN202080076776 A CN 202080076776A CN 114630668 A CN114630668 A CN 114630668A
- Authority
- CN
- China
- Prior art keywords
- csi
- crystal form
- form csi
- degrees
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 147
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- DKULOVKANLVDEA-UHFFFAOYSA-N ACT-132577 Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)N)=NC=NC=1OCCOC1=NC=C(Br)C=N1 DKULOVKANLVDEA-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 229940070148 aprocitentan Drugs 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 47
- 206010020772 Hypertension Diseases 0.000 claims abstract description 42
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims abstract description 4
- 230000009977 dual effect Effects 0.000 claims abstract description 4
- 239000002308 endothelin receptor antagonist Substances 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 36
- 239000007787 solid Substances 0.000 claims description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 239000012046 mixed solvent Substances 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229910002483 Cu Ka Inorganic materials 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 29
- 150000001875 compounds Chemical class 0.000 abstract description 26
- 238000011161 development Methods 0.000 abstract description 2
- 238000005457 optimization Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 23
- 238000009826 distribution Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 16
- 239000000126 substance Substances 0.000 description 13
- 239000012453 solvate Substances 0.000 description 12
- 238000000227 grinding Methods 0.000 description 11
- 238000003860 storage Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 238000002411 thermogravimetry Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000007906 compression Methods 0.000 description 7
- 230000006835 compression Effects 0.000 description 7
- 238000000113 differential scanning calorimetry Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- CNPVJWYWYZMPDS-UHFFFAOYSA-N 2-methyldecane Chemical compound CCCCCCCCC(C)C CNPVJWYWYZMPDS-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UHEIKHWCXFBABC-UHFFFAOYSA-N 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]pyrimidine-4-sulfonamide Chemical compound C=1C=C(Br)C=CC=1C=1C(S(=O)(=O)N)=NC=NC=1OCCOC1=NC=C(Br)C=N1 UHEIKHWCXFBABC-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229910017488 Cu K Inorganic materials 0.000 description 1
- 229910017541 Cu-K Inorganic materials 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- -1 hypertension Chemical compound 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940126589 solid medicine Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Aprocitentan(称为“化合物I”)的新晶型及其制备方法，含有该晶型的药物组合物，以及该晶型在制备双重内皮素受体拮抗剂药物和治疗难治性高血压药物中的用途。提供的Aprocitentan晶型具有一种或多种改进的性质，对未来该药物的优化和开发具有重要价值。
Description
PCT国内申请，说明书已公开。
Claims (11)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911073945 | 2019-11-07 | ||
| CN2019110739455 | 2019-11-07 | ||
| PCT/CN2020/122546 WO2021088645A1 (zh) | 2019-11-07 | 2020-10-21 | 一种Aprocitentan晶型及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114630668A true CN114630668A (zh) | 2022-06-14 |
| CN114630668B CN114630668B (zh) | 2024-02-27 |
Family
ID=75849413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080076776.5A Active CN114630668B (zh) | 2019-11-07 | 2020-10-21 | 一种Aprocitentan晶型及其制备方法和用途 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4056182A1 (zh) |
| CN (1) | CN114630668B (zh) |
| AU (1) | AU2020378025A1 (zh) |
| WO (1) | WO2021088645A1 (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101772494A (zh) * | 2007-08-17 | 2010-07-07 | 埃科特莱茵药品有限公司 | 4-嘧啶磺酰胺衍生物 |
| CN105992762A (zh) * | 2014-02-14 | 2016-10-05 | 埃科特莱茵药品有限公司 | 制造嘧啶磺酰胺衍生物的方法 |
| WO2018153513A1 (en) * | 2017-02-27 | 2018-08-30 | Idorsia Pharmaceuticals Ltd | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
| TW201924685A (zh) * | 2017-11-30 | 2019-07-01 | 瑞士商愛杜西亞製藥有限公司 | 用於治療內皮素相關疾病之4-嘧啶磺醯胺衍生物與sglt-2抑制劑之組合 |
-
2020
- 2020-10-21 AU AU2020378025A patent/AU2020378025A1/en active Pending
- 2020-10-21 WO PCT/CN2020/122546 patent/WO2021088645A1/zh unknown
- 2020-10-21 EP EP20884538.8A patent/EP4056182A1/en not_active Withdrawn
- 2020-10-21 CN CN202080076776.5A patent/CN114630668B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101772494A (zh) * | 2007-08-17 | 2010-07-07 | 埃科特莱茵药品有限公司 | 4-嘧啶磺酰胺衍生物 |
| CN105992762A (zh) * | 2014-02-14 | 2016-10-05 | 埃科特莱茵药品有限公司 | 制造嘧啶磺酰胺衍生物的方法 |
| WO2018153513A1 (en) * | 2017-02-27 | 2018-08-30 | Idorsia Pharmaceuticals Ltd | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
| CN110381948A (zh) * | 2017-02-27 | 2019-10-25 | 爱杜西亚药品有限公司 | 4-嘧啶磺酰胺衍生物的结晶形式 |
| TW201924685A (zh) * | 2017-11-30 | 2019-07-01 | 瑞士商愛杜西亞製藥有限公司 | 用於治療內皮素相關疾病之4-嘧啶磺醯胺衍生物與sglt-2抑制劑之組合 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020378025A1 (en) | 2022-06-23 |
| EP4056182A1 (en) | 2022-09-14 |
| CN114630668B (zh) | 2024-02-27 |
| WO2021088645A1 (zh) | 2021-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113242855B (zh) | 他发米帝司的晶型及其制备方法和用途 | |
| CN114929671B (zh) | 化合物i二盐酸盐的共晶及其制备方法和用途 | |
| AU2016203343A1 (en) | Salts of an epidermal growth factor receptor kinase inhibitor | |
| EP3156406A1 (en) | Crystalline forms of ribociclib free base | |
| CN111094290A (zh) | 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途 | |
| KR102657147B1 (ko) | 빌라스틴의 결정형 및 그의 제조 방법 | |
| CN114787152A (zh) | 一种bms-986165晶型及其制备方法和用途 | |
| CN112888692A (zh) | 一种Upadacitinib的晶型及其制备方法和用途 | |
| CN110156700A (zh) | 吉非替尼与水杨酸共晶体 | |
| CN112770756A (zh) | 一种Upadacitinib的晶型及其制备方法和用途 | |
| CN114605406A (zh) | Amg510化合物的晶型及其制备方法和用途 | |
| CN114621212A (zh) | Lanifibranor的晶型及其制备方法和用途 | |
| JP7295025B2 (ja) | （ｓ）－［２－クロロ－４－フルオロ－５－（７－モルホリン－４－イルキナゾリン－４－イル）フェニル］－（６－メトキシ－ピリダジン－３－イル）メタノールの結晶性形態 | |
| CN114787153A (zh) | 一种Resmetirom晶型及其制备方法和用途 | |
| WO2023193563A1 (zh) | 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物 | |
| WO2021063367A1 (zh) | 一种Resmetirom晶型及其制备方法和用途 | |
| CN114787154A (zh) | 一种Deucravacitinib的晶型及其制备方法和用途 | |
| WO2019134455A1 (zh) | Acalabrutinib的新晶型及其制备方法和用途 | |
| CN108640910A (zh) | 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体 | |
| CN114630668A (zh) | 一种Aprocitentan晶型及其制备方法和用途 | |
| WO2018196681A1 (zh) | 硝苯地平与异烟酰胺的共晶 | |
| WO2021197338A1 (zh) | 硝羟喹啉前药的晶型、含其的药物组合物及其制备方法和应用 | |
| WO2021000687A1 (zh) | Pac-1晶型的制备方法 | |
| CN115073430A (zh) | Belumosudil甲磺酸盐的晶型及其制备方法和用途 | |
| CN110291071B (zh) | Sb-939的盐的晶型及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |